I want to get continuous structured data on emerging functional ingredient properties, scientific studies, and regulatory status from global academic journals, research databases, and food authority websites.
Acquire continuous insights on functional ingredient properties and regulations — streamlined automation for informed decision-making
A saved example of what you can collect and monitor with Jsonify. Create your own version in Jsonify.
Build this in JsonifyYour original goal is prefilled.
Goal
I want to get continuous structured data on emerging functional ingredient properties, scientific studies, and regulatory status from global academic journals, research databases, and food authority websites.
Source coverage
- sciencedirect.com
- pubmed.ncbi.nlm.nih.gov
- researchgate.net
- jstor.org
- springer.com
- food.gov.uk
- efsa.europa.eu
- faostat.fao.org
- foodinsight.org
- ncbi.nlm.nih.gov
- nature.com
- wiley.com
Sample data
Illustrative sample data from the original configuration, not live or verified results.
| id | Source | Compound | Claimed Property | Study Type | Effect Size | Regulatory Status | Price | Last Updated | Availability |
|---|---|---|---|---|---|---|---|---|---|
| 1 | pubmed.ncbi.nlm.nih.gov | Luteolin-rich extract | Anti-inflammatory, NF-κB inhibition | Randomized crossover clinical trial (n=48) | Mean CRP reduction 18% (p=0.03) | Not evaluated by EFSA for health claim | $0.00 (research article) | 2026-01-31 | Full text |
| 2 | sciencedirect.com | Microencapsulated Curcumin (nanoemulsion) | Enhanced bioavailability, antioxidant | In vivo rodent pharmacokinetics | AUC increased 6.2x vs free curcumin | GRAS status pending for formulation | $35.00 (article) | 2026-01-29 | Paid |
| 3 | nature.com | Beta-glucan (oat) concentrate | Cholesterol-lowering, immune modulation | Meta-analysis of 12 RCTs | LDL reduction 7.5% (95% CI 4.1–10.9) | Health claim approved in some jurisdictions; EFSA outcome: 'substantiated' for bile-acid binding (not full chol lowering) | $0.00 (open access) | 2026-01-30 | Open |
| 4 | efsa.europa.eu | Steviol glycosides (rebaudioside M-rich blend) | Non-caloric sweetener, safe daily intake | EFSA re-evaluation report | Acceptable daily intake reaffirmed at 4 mg/kg bw/day | EFSA approved with specifications updated | €0.00 (report) | 2026-01-28 | Public |
| 5 | food.gov.uk | Vitamin D3-fortified yeast | Enhanced vitamin D status in vegans | Pilot human trial (n=30) | Serum 25(OH)D increase 9 ng/mL over 8 weeks (p<0.01) | Novel food consultation ongoing | £0.00 (technical note) | 2026-01-31 | Public |
| 6 | springer.com | Sodium alginate microbeads | Satiety enhancement, delayed gastric emptying | Double-blind RCT (n=82) | Reduced ad libitum energy intake 12% at 2h (p=0.04) | Food additive approved; claim under review | $29.99 (article) | 2026-01-30 | Paid |
| 7 | wiley.com | Anthocyanin-rich blackcurrant extract | Endothelial function improvement | Crossover human trial (n=24) | Flow-mediated dilation +1.8% (p=0.02) | No health claim authorized by EFSA | $45.00 (article) | 2026-01-29 | Paid |
| 8 | ncbi.nlm.nih.gov | Sodium butyrate microcapsules | Colonic health, epithelial repair | Preclinical porcine model | Increased mucosal crypt depth 15% (p<0.05) | Ingredient used in supplements; regulatory status varies | $0.00 (preprint) | 2026-01-31 | Preprint |
| 9 | researchgate.net | Fermented soybean peptide fraction (FK-23) | Blood pressure lowering | Open-label pilot (n=40) | Systolic BP reduction 6 mmHg at 12 weeks | Supplement marketed; country-specific claims | Free PDF | 2026-01-30 | Author upload |
| 10 | jstor.org | Medium-chain triglyceride (MCT) oil emulsions | Cognitive support in aging | Systematic review (older adults) | Small benefit on short-term memory; heterogeneity high | Food ingredient; no specific health claim allowed in EU | $12.00 (access) | 2026-01-28 | Paid |
| 11 | faostat.fao.org | €0.00 (data) | 2026-01-30 | Public | |||||
| 12 | foodinsight.org | Prebiotic inulin oligofructose blend | Promotes gut microbiota diversity | Randomized, placebo-controlled (n=120) | Bifidobacterium spp. increase 2.5-fold (p<0.001) | Novel food dossier submitted in EU | Free article summary | 2026-01-31 | Public |
| 13 | sciencedirect.com | Phospholipid-bound omega-3 (krill-derived) | Higher EPA/DHA plasma incorporation | Human PK trial (n=60) | EPA plasma increase 1.9x vs TAG form | Approved as ingredient; sustainability concerns noted | $39.99 (article) | 2026-01-29 | Paid |
| 14 | pubmed.ncbi.nlm.nih.gov | Nattokinase concentrate | Fibrinolytic activity, potential BP reduction | Meta-analysis of small RCTs | Modest BP reduction; overall evidence low certainty | Safety warnings in some countries (bleeding risk) | $0.00 (open access) | 2026-01-30 | Open |
| 15 | nature.com | Pea protein hydrolysate (bioactive peptides) | Muscle protein synthesis stimulation | Acute randomized trial in older adults (n=50) | MPS increased 18% vs control (p=0.01) | Ingredient generally recognized; claim under substantiation | $0.00 (article) | 2026-01-31 | Open |
| 16 | efsa.europa.eu | Novel alga Chlorella vulgaris oil | Source of DHA/PUFA for supplements | EFSA safety assessment | Toxicology: No genotoxicity; safe at proposed levels | Opinion: safe as novel food under specified conditions | €0.00 (report) | 2026-01-28 | Public |
| 17 | sciencedirect.com | Gingerol-enriched extract | Nausea reduction, gastric motility | Randomized placebo-controlled (n=90) | Symptom score improvement 22% (p=0.02) | Used as botanical supplement; claims vary by market | $29.95 (article) | 2026-01-30 | Paid |
| 18 | springer.com | Resistant starch type 4 (RS4) from tapioca | Postprandial glucose attenuation | Acute human trial (n=36) | 2-hr glucose iAUC reduced 28% (p=0.01) | Approved as dietary fiber ingredient; labeling allowed in some regions | $24.99 (article) | 2026-01-29 | Paid |
| 19 | wiley.com | Zinc-L-methionine chelate | Improved bioavailability vs zinc oxide | Controlled absorption study (n=20) | Serum zinc AUC +32% (p=0.04) | Nutrient form used in supplements; permitted | $39.00 (article) | 2026-01-31 | Paid |
| 20 | ncbi.nlm.nih.gov | Polyphenol-rich apple pomace extract | Blood glucose regulation, antioxidant | Pilot RCT (n=60) | HbA1c reduction 0.2% non-significant at 12 weeks | Ingredient marketed; health claims limited | $0.00 (open access) | 2026-01-30 | Open |
| 21 | researchgate.net | Cannabidiol (CBD) isolate in food matrices | Anxiety reduction, sleep improvements | Observational consumer survey (n=1,200) | Self-reported sleep quality improvement 31% | Regulatory restrictions varied; EFSA safety data requested | Free download | 2026-01-27 | Author upload |
| 22 | jstor.org | Feruloylated oligosaccharides from rice bran | Antioxidant, skin photoprotection | In vitro + small human skin patch study | Reduced UV-induced erythema by 15% (p=0.05) | Cosmetic ingredient status; ingestion claims limited | $10.00 (access) | 2026-01-29 | Paid |
| 23 | faostat.fao.org | €0.00 (data) | 2026-01-31 | Public | |||||
| 24 | foodinsight.org | Sodium-reduced sea salt alternative (potassium chloride blend) | Lower sodium intake with similar taste | Consumer acceptability trial (n=400) | Taste acceptability maintained; Na intake reduced 18% | Ingredient widely used; labeling required for K content in some countries | Free article | 2026-01-30 | Public |
| 25 | sciencedirect.com | Protein glycation inhibitors (pyridoxamine analogs) | AGE formation reduction | Animal diabetic model | Tissue AGE markers reduced 40% (p<0.01) | Investigational; not authorized for food use | $44.99 (article) | 2026-01-31 | Paid |
| 26 | pubmed.ncbi.nlm.nih.gov | Bovine colostrum concentrate | Gut barrier support, reduced diarrhea incidence | Double-blind RCT in athletes (n=150) | Incidence of GI symptoms 26% vs 43% in placebo (p=0.01) | Marketed as supplement; specific claims regulated | $0.00 (open access) | 2026-01-30 | Open |
| 27 | efsa.europa.eu | Synthetic Allulose crystalline powder | Low-calorie sweetener alternative | EFSA evaluation of safety and labeling | Metabolic profile acceptable; labeling guidance provided | EFSA opinion supports use with maximum levels in certain categories | €0.00 (report) | 2026-01-28 | Public |
| 28 | nature.com | Human milk oligosaccharide analog (2'-FL) from microbial fermentation | Infant microbiota modulation, immune support | Randomized infant formula trial (n=300) | Reduced incidence of respiratory infections by 12% (p=0.04) | Approved for use in infant formula in multiple markets | $0.00 (article) | 2026-01-31 | Open |
Insights and analytics
- Total Research Papers Analyzed (metric)
- Emerging Ingredient Research Trends Over Time (line)
- Top 5 Functional Ingredients by Research Volume (bar)
- Distribution of Research by Ingredient Type (donut)
- Latest Scientific Studies on Functional Ingredients (table)
- Regulatory Status of Key Ingredients (horizontal_bar)
- Key Findings on Ingredient Properties (insights)
- Cumulative Number of Studies Published Annually (area)
- Active Research Databases Monitored (metric)
- Regulatory Changes Over Time (line)
- Research Articles by Source (table)
- Study Focus Areas (Health, Nutrition, Safety) (pie)
Change notifications
- New Study Published — new research available sciencedirect.com
- Regulatory Status Changed — regulatory status updated efsa.europa.eu
- Availability Change Detected — is now available again food.gov.uk
- Coverage Gap Identified — missing from latest studies pubmed.ncbi.nlm.nih.gov
- New Article Available — just published nature.com
Integrations and delivery
- api
- snowflake
Make this your own
Start with this goal in Jsonify, then choose the sources and data you need.
Build this in Jsonify